章彬 博士 个人简历
Dr. Bin Zhang – Curriculum Vitae

宁波大学 食品与药学学院 海洋药学系
Marine Pharm Department, College of Food and Pharmaceutical
Sciences, Ningbo University
中共党员；职称：助理研究员 Assistant Research Scientist
化学博士 Ph.D in Chemistry；研究方向：药物化学Medicinal Chemistry
ORCID：0000-0002-4371-4746
科研主页：https://www.researchgate.net/profile/Bin-Zhang-163
邮箱 Emails：zhangbin1@nbu.edu.cn; binzhang86@126.com

一、教育与工作经历 Education and Professional Experience：

2004.09 - 2008.07 安徽理工大学 制药工程（化学） 理学学士
Bachelor in Pharmaceutical Engineering, Department of Chemical Engineering, Anhui University of Science Technology
2008.09 - 2011.07 北京工业大学 生物化学与分子生物学 理学硕士
Master in Biochemistry and Molecular Biology, College of Life Science and Bioengineering, Beijing University of Technology
2011.09 - 2015.07 清华大学 化学 理学博士
Ph.D in Chemistry, Department of Chemistry, Tsinghua University, China
2015.07 - 2017.07 沈阳药科大学 药物化学 博士后
Post-Doctor, School of Pharmacy, Shenyang Pharmaceutical University
2017.08 - 2018.06 宁波大学 海洋学院 海洋药学系 助理研究员
Ningbo University, College of Marine Sciences, Department of Marine Pharmacy, Assistant Research Scientist
2018.06 - 至今 宁波大学 食品与药学学院 海洋药学系 助理研究员
Ningbo University, College of Food and Pharmaceutical Sciences, Assistant Research Scientist

二、主讲本科专业课程 Teaching Experience：

课程号
课程中文名称
课程英文名称
学生评教成绩
（满分100）

EK5J28A00
天然药物化学
Natural Medicinal Chemistry
暂无（科院）

132Y03H
海洋药学综合实验
Comprehensive Marine Pharmacy Experiments
90.00

133X02G
药物化学实验
Medicinal Chemistry Experiments
95.56

133D07A
药物合成
Drug Synthesis
97.85

133X03A
药理学
Pharmacology
90.00

133X03G
药理学实验
Pharmacology Experiments
84.44

133D07B
药物合成实验
Drug Synthesis Experiments
96.58

137D05J
海洋药物前沿讲座
Frontiers in Marine Pharmacy
96.27



三、学生培养 Students：

1. 2018年9月起，聘为18级海洋药学本科生班主任。
2. 目前指导硕士研究生3名；作为本科生导师，培养本科生9名。其中，1名16级海药专业本科生获校级优秀毕业论文。
3. 指导本科生团队获宁波大学SRIP（Student Research and Innovation Program）重点项目2项，宁波大学第十届生科赛（The 10th Undergraduate Life Science Contest）三等奖。

四、科研方向 Research Interest：

1. 小分子靶向抑制剂（分子探针）的设计、合成及生物学机理研究（抗癌、抗AD、抗菌等）。Small molecule drug design, synthesis and biological evaluation.
2. 天然产物（海洋来源）的结构优化与活性研究。
Structural modification/optimization of marine natural products.

五、主持/参与的科研项目 Research Grants：

1． 靶向DNMT/HDAC小分子抑制剂的设计、合成及抗癌研究，国家重点实验室开放基金（Open Foundation of the State Key Laboratory），2020.01-2020.12, 10万，主持。
2． 伊维菌素氨基衍生物及其衍生化分子探针的合成，企业横向项目（Horizontal Scientific Research Project），2019.07-2021.06，10万，主持。
3． 基于吖啶母核的抗肿瘤抑制剂的设计、合成及活性研究，宁波大学科研启动金（Scientific Research Project of Ningbo University），2017.08-2019.12，5万，主持。
4． 基于拓扑异构酶（Topo II）与HDAC双靶点抑制剂的设计、合成及生物学研究，宁波市自然科学基金 (Sci & Tech Project of Ningbo, 2018A610410)， 2018.11-2020.10，3万，主持。
5． 宁波大学科研项目（The Research Fund of Ningbo University, XYL18004），2018.01-2019.12，0.6万，主持。
6． 深海药用动植物资源多样性及其可利用潜力的挖掘，2018.08-2021.12，国家科技部/国家重点研发计划（National Key Research and Development Project, 2018YFC**），217万，参与。


六、发表论文 Publications：

1. Z.D. Dou, X.P. He, P. Xu, B. Zhang*, L.J. Ding*, Rapid separation and purification of two C25 steroids with bicyclic [4.4.1] A/B rings from the marine fungus Aspergillus sp. LS116 by high-speed counter-current chromatography in stepwise elution mode. Natural Product Research, 2021, Online. DOI: https://doi.org/10.1080/**.2021.**.（IF 2.158）
2. X. Tan¹; H. Xie¹, B. Zhang¹; J. Zhou, Z.D. Dou, X. Wang*, N. Wang*, A Novel Ivermectin-Derived Compound D4 and Its Antimicrobial/Biofilm Properties against MRSA. Antibiotics, 2021, 10, 208. （IF 3.893）
3. Q.T. Zhang, Z.D. Liu, Z. Wang, T. Wang, N. Wang, N. Wang*, B. Zhang*, Y.F. Zhao, Recent Advances in Small Peptides of Marine Origin in Cancer Therapy. Marine Drugs, 2021, 19, 115.（IF 4.073）
4. B. Zhang, J.M. Zou, Q.T. Zhang, Z. Wang, N. Wang*, S. He, Y.F. Zhao, C. B. Naman*, Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy. International Journal of Molecular Sciences, 2021, 22: p. 2408.（IF 4.556）
5. T. Wang, Q.T. Zhang, N. Wang*, Z.Q. Liu, B. Zhang*, Y.F. Zhao, Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. Current Medicinal Chemistry, 2021, Online. DOI: 10.2174/44（IF 4.184）
6. B. Zhang, T. Zhang, T.Y. Zhang, N. Wang*, S. He, B. Wu, H.X. Jin*, A Novel Methoxybenzyl 5-Nitroacridone Derivative Effectively Triggers G1 Cell Cycle Arrest in Chronic Myelogenous Leukemia K562 Cells by Inhibiting CDK4/6-Mediated Phosphorylation of Rb. International Journal of Molecular Sciences, 2020, 21: p. 5077.（IF 4.556）
7. B. Zhang, Q.T. Zhang, Z.D. Liu, N. Wang*, H.X. Jin, F. Liu, C.L. Zhang, S. He*, Synthesis and Anticancer Research of N‐(2‐aminophenyl)benzamide Acridine Derivatives as Dual Topoisomerase I and Isoform‐Selective HDAC Inhibitors. ChemistrySelect, 2020, 5: p. 8311-8318.（IF 1.811）
8. B. Zhang, T. Zhang, J.Z. Xu, J. Lu, P.P. Qiu, T.T. Wang, L.J. Ding*. Marine Sponge-Associated Fungi as Potential Novel Bioactive Natural Product Sources for Drug Discovery: A review. Mini Reviews in Medicinal Chemistry, 2020, 20, 1966-2010.（IF 2.733）
9. M.Q. Yi, S.X. Lin, B. Zhang, H.X. Jin, L.J. Ding*, Antiviral potential of natural products from marine microbes. European Journal of Medicinal Chemistry, 2020, 207, p. 112790.（IF 5.572）
10. B. Zhang, Z.D. Dou, Z. Xiong, N. Wang*, S. He, X.J. Yan, H.X. Jin*, Design, synthesis and biological research of novel N-phenyl benzamide-4 methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents, Bioorganic & Medicinal Chemistry Letters, 2019, 23: p. 126714.（IF 2.572）
11. T. Li, N. Wang, T. Zhang, B. Zhang*, T.P. Sajeevan, V. Joseph, L. Armstrong, S. He, X.J. Yan and C.B. Naman*, A Systematic Review of Recently Reported Marine Derived Natural Product Kinase Inhibitors, Marine Drugs, 2019, 17: p. 493.（IF 4.073）
12. J.B. Hu*, C.L. Yang, H.B. Wang, J. Li, X.Y. Tan, J.H. Wang, B. Zhang* and Y.F. Zhao, An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2019, 20: p. 1679-1687.（IF 2.878）
13. N. Wang, P.P. Qiu, W.Cui, X.J. Yan, B. Zhang* and S. He*, Recent advances in multi-target anti-Alzheimer disease compounds (2013 up to present), Current Medicinal Chemistry, 2019, 26: p. 5684-5710. （IF 4.184）
14. X.P. He, L. Ren, L.J. Ding*, J. Xu, B. Zhang, W. Zhang, S. He*, Penichrypyrone A: A New γ-Pyrone Derivative from the Sponge-Derived Fungus Penicillium chrysogenum LS18. Natural Product Communications, 2019, 14 (6), **X**.（IF 0.468）
15. L. Huang, L.J. Ding*, X. Li, N. Wang, Y. Yan, M. Yang, W. Cui, C. N. Benjamin, K. Cheng, W.Y. Zhang, , B. Zhang, H.X. Jin, S. He*, A new lateral root growth inhibitor from the sponge-derived fungus Aspergillus sp. LS45. Bioorganic & medicinal chemistry letters, 2019, 29 (13), p. 1593-1596.（IF 2.572）
16. W. Li, L.J. Ding*, N. Wang, J. Xu, W.Y. Zhang, B. Zhang, S. He, B. Wu, H.X. Jin*, Isolation and characterization of two new metabolites from the sponge-derived fungus Aspergillus sp. LS34 by OSMAC approach. Marine drugs, 2019, 17 (5), p. 283.（IF 4.073）
17. N. Wang¹, B. Zhang¹, F. Jin, D. Gao*, F. Liu, H. X. Liu, Y. Y. Jiang, Combing metabolomics with bioanalysis methods to study theantitumor mechanism of the new acridone derivative 8q on CCRF-CEM cells: 8q induced mitochondrial-mediated apoptosis andtargeted the PI3K/AKT/FOXO1 pathway. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160: p. 314-322.（IF 3.209）
18. N. Wang, S. Chen, B. Zhang, S. Li, F. Jin, D. Gao*, H. Liu, Y. Jiang, 8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metastasis through HSP90alpha downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells, Scientific Reports, 2018, 8: p. 309.（IF 3.998）
19. B. Zhang¹, N. Wang¹, C.L. Zhang, C.M. Gao*, W. Zhang, K. Chen, W.B. Wu, Y.Z. Chen, C.Y. Tan, Y.Y. Jiang*, Novel multi-substituted benzyl acridone derivatives as survivin inhibitors for hepatocellular carcinoma treatment. European Journal of Medicinal Chemistry, 2017, 129: p. 337-348.（IF 5.572）
20. Z.S. Cui, , X. Li, B. Li, B. Zhang*, C. M. Gao*, Y. Chen, C. Tan, H. Liu, W. Xie, T. Yang, Y.Y. Jiang, Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment. Bioorganic & Medicinal Chemistry, 2016, 24(2): p. 261-269.（IF 3.073）
21. W. Zhang, B. Zhang, W. Zhang, T. Yang, N. Wang, C.M. Gao, C. Tan, H. Liu, and Y.Y. Jiang, Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors. European Journal of Medicinal Chemistry, 2016, 116: p. 59-70.（IF 5.572）
22. Chen, C¹., H. Liu¹, B. Zhang², Y. Wang, K. Cai, Y. Tan, C.M. Gao, H. Liu, C. Tan, and Y.Y. Jiang, A simple benzimidazole quinoline-conjugate fluorescent chemosensor for highly selective detection of Ag⁺. Tetrahedron, 2016, 72(27-28): p. 3980-3985.（IF 2.379）
23. W.L. Li, X. Li, B. Zhang, C.M. Gao, Y.Z. Chen, and Y.Y. Jiang, Current Progresses and Trends in the Development of Progesterone Receptor Modulators. Current Medicinal Chemistry, 2016, 23(23): p. 2507-2554.（IF 3.894）
24. B. Zhang, K. Chen, N. Wang, C. M. Gao*, Q. Sun, L. Li, Y. Chen, C. Tan, H. Liu, Y.Y. Jiang*, Molecular design, synthesis and biological research of novel pyridyl acridones as potent DNA-binding and apoptosis-inducing agents. European Journal of Medicinal Chemistry, 2015, 93: p. 214-226.（IF 5.572）
25. C.M. Gao, B. Li², B. Zhang², Q. Sun, L. Li, X. Li, C. Chen, C. Tan, H. Liu, and Y.Y. Jiang, Synthesis and biological evaluation of benzimidazole acridine derivatives as potential DNA-binding and apoptosis-inducing agents. Bioorganic & Medicinal Chemistry, 2015, 23(8): p. 1800-1807.（IF 2.802）
26. Y. Wang, J. Rong, B. Zhang, L.M. Hu, X. Wang, and C. Zeng, Design and synthesis of N-methylpyrimidone derivatives as HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry, 2015, 23(4): p. 735-41.（IF 2.802）
27. X. Li, C.M. Gao, T. Yang, B. Zhang, C. Tan, H. Liu, and Y.Y. Jiang, A POCl₃-mediated synthesis of substituted fused azoacridones derivatives. RSC Advances, 2015, 5(36): p. 28670-28678.（IF 3.049）
28. B. Zhang, X. Li, B. Li, C.M. Gao*, Y.Y. Jiang*, Acridine and its derivatives: a patent review (2009-2013). Expert Opinion on Therapeutic Patents, 2014, 24(6): p. 647-664.（IF 5.611）
29. J.J. Tan¹, B. Zhang¹, X. Jing Cong, L. Fu Yang, B. Liu, R. Kong, Z. Yao Kui, C. Xin Wang, and L. Ming Hu, Computer-aided design, synthesis, and biological activity evaluation of potent fusion inhibitors targeting HIV-1 gp41. Medicinal Chemistry, 2011, 7(4): p. 309-316.（IF 2.631）
30. L.F. Yang, X. Xu, Y. Huang, B. Zhang, C. Zeng, H. He, C. Wang, and L. Hu, Synthesis of polyhydroxylated aromatics having amidation of piperazine nitrogen as HIV-1 integrase inhibitor. Bioorganic & Medicinal Chemistry Letters, 2010, 20(18): p. 5469-71.（IF 2.448）


七、专利申请 Patents：

1. 章彬，崔巍，何山，张盼盼，王宁，邹佳美，刘志文. 一种1,2,3,4-四氢吖啶-9-胺类化合物及其制备方法和用途，申请号：2.8，申请日：2020.11.04。
2. 邹佳美、赵玉铉、严小雪、章彬、何山，便于移动的微生物培养装置，CNU. 已授权，授权日：2020.10.30。
3. Slava Epstein; 章彬; 王银达; 王宁; 何山. 一种多取代色胺基苯甲酰胺类化合物及其制备方法和用途，CNA，申请日：2020.01.16。
4. 章彬; 何山; 王宁; Slava Epstein. 一种N-邻取代苯基苯甲酰胺-4-甲氨基吖啶类化合物及其制备方法和用途，CNA，申请日：2019.11.04。
5. Slava Epstein; 章彬; 何山; 王宁; 金海晓. 一种4-甲氨基吖啶-N-苯基苯甲酰胺类化合物及其制备方法和用途，CNA. 申请日：2019.07.30。
6.多取代苯基烷氨基吖啶酮-4-酰胺类化合物及其制备方法和用途，已授权（CNB，排名第2）。
7. 一种氮杂芳环烷基氨基吖啶酮-4-酰胺类化合物及其制备方法与应用，已授权（CNB，排名第3）。
8. 1-N-取代基-6-吡唑亚甲基喹啉-4-酮-3-甲酸类化合物及其制备方法和应用（CNA，排名第2）。
9. 多取代嘧啶酮类化合物及其制备方法和应用，已授权（CNB，排名第3）。